GCM
XERS icon

Graham Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History

Graham Capital Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Sell
16,266
-10,896
-40% -$69.6K ﹤0.01% 1119
2026
Q1 		$158K Buy
+27,162
New +$180K ﹤0.01% 991
2025
Q3 		– Sell
-125,417
Closed -$586K – 1697
2025
Q2 		$586K Sell
125,417
-8,251
-6% -$37.8K 0.01% 757
2025
Q1 		$734K Buy
133,668
+63,006
+89% +$254K 0.01% 652
2024
Q4 		$240K Buy
70,662
+17,209
+32% +$55.4K ﹤0.01% 1019
2024
Q3 		$152K Sell
53,453
-1,688
-3% -$4.33K ﹤0.01% 968
2024
Q2 		$124K Sell
55,141
-31,478
-36% -$63.4K ﹤0.01% 918
2024
Q1 		$191K Buy
86,619
+49,835
+135% +$129K ﹤0.01% 906
2023
Q4 		$86.4K Sell
36,784
-20,625
-36% -$38.1K ﹤0.01% 916
2023
Q3 		$107K Buy
+57,409
New +$132K ﹤0.01% 933

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Graham Capital Management's XERS Position: Q2 2026 in Review

Graham Capital Management reduced its Xeris Biopharma Holdings (XERS) stake by 40% in Q2 2026, selling an estimated $69.6K and leaving 16,266 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #1119.

Graham Capital Management first reported a position in XERS in Q3 2023 and has held it in 10 quarters since. The position peaked at $734K in Q1 2025. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Graham Capital Management held 16,266 shares of Xeris Biopharma Holdings worth $129K as of Q2 2026.
  • Graham Capital Management sold 10,896 Xeris Biopharma Holdings shares in Q2 2026, an estimated $69.6K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Graham Capital Management's portfolio in Q2 2026, its #1119 holding.
  • Graham Capital Management first reported a position in Xeris Biopharma Holdings in Q3 2023 and has held it in 10 quarters since.
  • Graham Capital Management's Xeris Biopharma Holdings position peaked at $734K in Q1 2025.
  • 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.